AVI BioPharma 2004 News Archive

December

AVI BioPharma Announces NeuGene Antisense Collaboration With the Walter Reed Army Institute of Research December 21, 2004, Portland, Oregon
AVI BioPharma Updates Third-Generation NeuGene Antisense Program December 8, 2004, Portland, Oregon

November

AVI BioPharma Reports Final Results From Resten-NG AVAIL Clinical Trial and Updates Its Cardiovascular Restenosis Program November 10, 2004, Portland, Oregon
Third Quarter Financial Results Conference Call Transcript November 9, 2004, Portland, Oregon
AVI BioPharma Announces Third Quarter Financial Results November 4, 2004, Portland, Oregon
AVI BioPharma and USAMRIID Announce NeuGene Antisense Drug Demonstrates Efficacy Against Ebola Virus November 1, 2004, Portland, Oregon

October

AVI BioPharma NeuGene Antisense Drugs Suppress Influenza A Virus October 29, 2004, Portland, Oregon
AVI BioPharma Announces 2004 Third Quarter Financial Results Conference Call October 28, 2004, Portland, Oregon
Written Testimony of Alan P. Timmins: BioShield II: Responding to An Ever-Changing Threat October 6, 2004, Portland, Oregon
AVI BioPharma to Testify Before Congressional Committee On Legislative Proposal for BioShield II October 6, 2004, Portland, Oregon

September

AVI BioPharma Presents at UBS Global Life Sciences Conference September 27, 2004, Portland, Oregon
AVI BioPharma Presents Antisense Approach to Transplant Acceptance By Regulating Activated Lymphocytes September 10, 2004, Portland, Oregon

August

AVI BioPharma Announces Initiation of Acute West Nile Virus Clinical Study August 31, 2004, Portland, Oregon
AVI BioPharma Announces Dengue Virus Collaboration With CDC August 23, 2004, Portland, Oregon
AVI BioPharma Announces NeuGene Antisense Collaboration With USAMRIID on Biodefense Agents August 10, 2004, Portland, Oregon
Second Quarter Financial Results Conference Call Transcript August 5, 2004, Portland, Oregon
AVI BioPharma Announces Second Quarter Financial Results August 5, 2004, Portland, Oregon

July

AVI BioPharma Receives Notice of Allowance for Key Patent Application Covering NeuGene Antisense Technology for RNA Viruses July 21, 2004, Portland, Oregon

June

AVI BioPharma Announces Termination of Cardiovascular Agreement With Medtronic June 30, 2004, Portland, Oregon
U.S. Senate Committee on Appropriations Directs $10 Million For Defense-Related Research to AVI BioPharma June 24, 2004, Portland, Oregon
AVI BioPharma’s NeuGene Antisense Shows Inhibition of Dengue Virus June 1, 2004, Portland, Oregon

May

Journal of Virology Publication Highlights Antiviral Activity Of AVI BioPharma’s NeuGene Antisense Compound May 20, 2004, Portland, Oregon
AVI BioPharma Announces First Quarter Financial Results May 5, 2004, Portland, Oregon
AVI BioPharma Presents Additional Data on West Nile Virus Clinical Trial At International Antiviral Conference May 4, 2004, Portland, Oregon

April

AVI BioPharma Announces 2004 First Quarter Financial Results Conference Call April 28, 2004, Portland, Oregon
AVI BioPharma Expands Management Team April 5, 2004, Portland, Oregon
AVI BioPharma Reports Anti-Cancer Effects and Single-Dose Bioavailability With NeuGene Antisense Compounds April 1, 2004, Portland, Oregon

March

AVI BioPharma Announces Additions to Board of Directors March 22, 2004, Portland, Oregon
AVI Reports Positive Clinical Results On Oral Delivery of Its NeuGene Antisense Drug March 18, 2004, Portland, Oregon
AVI BioPharma Announces 2003 Fourth Quarter and Full Year Financial Results March 9, 2004, Portland, Oregon

January

AVI BioPharma Announces Exercise of Warrants January 27, 2004, Portland, Oregon
AVI BioPharma Reports Successful NeuGene Antisense Approach To Regulation of the Immune Response in Transplantation January 26, 2004, Portland, Oregon
AVI BioPharma Reports Inhibition of SARS Coronavirus With NeuGene Antisense Drugs January 9, 2004, Portland, Oregon
AVI BioPharma Bolsters Clinical and Regulatory Expertise January 8, 2004, Portland, Oregon

About AVI BioPharma

Technology

Communication